Illumina Inks Supply Agreement with Natera for NIPT | GenomeWeb

NEW YORK (GenomeWeb News) – Illumina said today that it has entered into a three-year supply agreement with Natera, under which Natera will run its noninvasive prenatal test Panorama on Illumina's HiSeq 2500 and use the associated Illumina consumables.

"This deal enables a major expansion of Natera's laboratory capacity to support the fast-growing demand for our Panorama test," Natera CEO Matthew Rabinowitz said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: tool to discover copy number variants, single-nucleus RNA sequencing study of myoblasts, and more.

A study of Tasmanian devil genomes suggests they are evolving resistance to devil facial tumor disease.

Theranos has withdrawn its request for emergency clearance of a Zika virus blood test, according to the Wall Street Journal.

An assistant professor who was fired from Mount Sinai School of Medicine has allegedly shot the school's dean, the New York Times reports.